Title21 Health Solutions is the only end-to-end software provider for cell & gene therapy labs. Its software digitizes all processes, thereby reducing paperwork, optimizing workflow productivity, improving traceability, regulatory compliance, and overall patient safety.

ArchiMed reinforces its focus in the healthcare software space by investing in Phoenix, Arizona-based Title21 Health Solutions. The Trans-Atlantic private healthcare specialist is acquiring a majority of Title21. The investment was sourced through a direct contact - initiated by ArchiMed - to founders Lynn Fischer and Kent Kirimli, via ArchiMed’s proprietary MedDiscover® platform. Founders and management of Title 21 will retain a significant minority stake. ArchiMed is making the investment through its MED III fund, which closed on €650 million in August, after only two months of fundraising.

Founded in 2001 and named after the regulatory code governing the food and drug industries in the United States, Title21 is the world’s largest and most highly specialized provider of paperless electronic services to cell & gene therapy labs. Title21’s clients include globally preeminent hospital and research institutions, including the Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford University, Kaiser Permanente, and the University of Pennsylvania Health System. The fast-growing cell & gene therapy industry is transforming the treatment of life-threatening conditions including genetic disorders such as spinal muscular atrophy, as well as diseases caused by vital infection, including COVID-19. McKinsey & Company estimates that only 20 percent of cell & gene therapy labs are currently digitized.

“ArchiMed stood out from other potential partners,” says Lynn Fischer, CEO of Title21. “They share our sense of urgency when it comes to supporting the commercialization of advanced therapies through efficient, easily traceable and scalable technology. They impressed us with their deep domain expertise and track record in cell and gene therapy and as a global leader in healthcare software investing. We couldn’t have found a better partner with whom to scale.” ArchiMed’s investments in healthcare software include Cardioline, a specialist in remote cardiology testing, and ActiGraph, a developer of wearable, remote technology for drug trials. ArchiMed’s investments in cell & gene therapy include, Polyplus, Clean Biologics and Xpress Biologics.

“Title21 is clearly the best candidate to accelerate digitization in the cell and gene therapy space, not just in the US, but globally,” says ArchiMed Founding Partner Vincent Guillaumot. “Title21’s technology is the most advanced in the world when it comes to ease-of-use, scalability and breadth of offering. As part of this new partnership, we’ll leverage long-established relationships with US hospital groups, accelerate the group’s research and development and help Title21 expand rapidly in Europe and Asia.”

ArchiMed can more than double its investment in Title21 to support growth. It’s also appointing three C-Suite executives to the board, Peter Bailey, Brian Smith and Dan Drawbaugh. Both Bailey and Smith are part of ArchiMed’s MedTalents®, a global network of ArchiMed-associated senior healthcare executives who identify, facilitate and advise on deals and counsel portfolio companies. Bailey was the former CEO of LabVantage and currently sits on the Board of Xybion, a prominent laboratory information management software company. Smith, an Operating Partner at ArchiMed, is currently the Chairman and CEO of ArchiMed-owned Ad-Tech, which makes minimally invasive brain electrodes featuring ease of use and connectivity. Drawbaugh is currently CEO of the Steadman Clinic, and formerly CIO at the University of Pittsburgh Medical Center.

“Specialized software continues to penetrate the healthcare space to optimize workflows. We can leverage both our software knowledge and expertise in cell and gene therapy to support Title21’s next phase of growth,” adds Guillaumot.

MED III invests in small-cap healthcare sectors in Europe and the Americas, partnering with owners and managers. The fund’s other investments are Cardioline and Corealis Pharma. The latter provides outsourced formulation development and manufacturing of tablets, capsules and granules for preclinical and clinical trials.

About ArchiMed - www.archimed.group - With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include Biopharmaceutical Products & Services, Life Science Tools, Medical Devices & Technologies, Diagnostics, Health Technologies & Software and Consumer Health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small- to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages €5 billion across its various funds. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.

About Title21 - www.title21.com -Since 2001, Title21 Health Solutions has been dedicated to delivering easy-to-use, flexible and integrated technology to support health sciences organizations achieve compliance, gain efficiencies and ensure high quality, ultimately, to support improvement in patient safety and care. Their sole focus is developing technology to meet the specific needs of healthcare and life sciences firms, resulting in comprehensive solutions that are flexible to evolving business and regulatory requirements. Through the years, their partnerships with industry leaders have steered their innovations to continue to meet the dynamic needs of the markets they serve. As the breadth of Title21’s technology solutions has expanded, their mission and dedication to customers’ success and supporting the improvement of patient care has served as the true north. For the team at Title21 Health Solutions, their passion is to deliver technology that better enables customers to deliver products and services that truly make a difference and enable world class patient care.

Contacts - France: Stéphanie du Ché, stephanie.duche@archimed.group, +33 (0)6 16 36 11 08;

International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76

Back